Tuesday February 22, 6:03 am Eastern Time
Company Press Release
SOURCE: BSD Medical Corporation
National Television Introduces BSD Medical and Hyperthermia to America
SALT LAKE CITY, Feb. 22 /PRNewswire/ -- BSD Medical Corp. (OTC Bulletin Board: BSDM - news) announced today the Sunday national airing on CNBC of the Emmy award-winning series, Today's Health, featuring BSD Medical and Hyperthermia. The series also airs in national broadcast syndication to approximately 73% of the country through network affiliates and independents. The approximate reach is 65 million households. Today's Health is also seen internationally in 38 countries, which includes NBC Asia international syndication.
``Until now, the problem has been exposure,' said BSD President, Hyrum A. Mead. ``We are delighted to have America and the rest of the world learn about BSD Medical Corporation and our important technology for the treatment of cancer. The mid-day broadcast time was excellent, as many families are at home during the day on Sunday. Further, nearly everyone is affected by cancer, and the subject naturally draws interest.'
In introducing Hyperthermia, broadcast journalist and show host Faith Daniels stated, ``The struggle against cancer requires our best and brightest innovations. Hyperthermia is another powerful treatment that gives us one more weapon against the second leading cause of death in America. This promising therapy uses focused heat, and the result may be widespread hope.'
The program drew on the clinical experience and insights of medical experts around the world. Dr. Gerard van Rhon of Rotterdam said, ``The power of Hyperthermia is that it increases the effect of conventional techniques such as radiotherapy (radiation) or chemotherapy. Besides enhancing the effects, it has no toxicity, so it does not harm the patient.' Regarding this increased effect, Dr. Clare Vernon from London stated, ``Hyperthermia trials are consistently showing a 20-30% improvement on the treatment results we had before, and that is such a big improvement.' Speaking on the clinical applications of Hyperthermia, Dr. Ajmel Puthawala of Long Beach Memorial Hospital said, ``Head and neck cancers, breast cancers, some pelvic cancers like prostate cancer and gynecologic cancers are the sites that can be treated well with Hyperthermia.'
The program demonstrated the BSD-2000, explaining that ``the treatment of cancer using Hyperthermia relies on advanced equipment, like the BSD-2000 developed by BSD Medical Corporation. The BSD-2000 can precisely deliver heat treatments into the malignant region without harming healthy tissue.' Dr. Steven Stroup of Nashville explains BSD-2000 treatment planning. ``You take a look at the body in sections,' he says, ``like we do with CT scans or MRI scans, and you can study, three dimensionally, the tumor in the normal tissue. Then you do planning. You do mock computerized setups of heating and look at heating patterns in those patients. That gives you an ability to plan your heating deposition and steer that heating to exactly where you want it.'
Regarding further sophistication of the BSD-2000, a pre-broadcast press release from Five Star Productions states, ``Much of BSD Medical's equipment has already received FDA approval, and the company continues to aggressively advance the state-of-the-art of Hyperthermia treatment with new equipment. The new BSD-2000-3D/MR, for example, combines the high technology concepts of 3-D heating pattern shaping, 3-D patient-specific treatment planning and Magnetic Resonance Imaging (MRI).'
The broadcast was timely, as BSD had announced only January 27, 2000, receipt of the CE Mark for the BSD-2000. From a marketing perspective, the CE Mark provides in Europe the same advantage as an FDA approval in the United States.
BSD has obtained rights to reproduction and distribution of this program for further use both in the United States and abroad. More information about BSD Medical Corporation can be found by visiting the website at www.bsdmc.com.
Statements contained in this press release that are not historical facts are forward looking statements, as that item is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties (detailed in the Company's findings with the Securities and Exchange Commission) that could cause actual results to differ materially from estimated results.
SOURCE: BSD Medical Corporation
--------------------------------------------------------------------------------
More Quotes and News: BSD Medical Corp (OTC BB:BSDM.OB - news)
Related News Categories: biotech, medical/pharmaceutical
--------------------------------------------------------------------------------
SOURCE: BSD Medical Corporation
BSD Medical Shares Up 1500% - Issues Eighteen Month Milestone Report
SALT LAKE CITY, Feb. 22 /PRNewswire/ -- BSD Medical Corp. (OTC Bulletin Board: BSDM - news) today released a milestone report to acquaint its substantial influx of new investors and inquirers with the company's key objectives and accomplishments over the past eighteen months. Hyrum Mead, President of BSD Medical said, ``With the very significant rise in investor interest as the stock value has escalated (as of Friday's close up 1518% since the beginning of last fiscal year), we have been flooded with questions, particularly from new and prospective investors, about the company's objectives and accomplishments. We therefore felt it important to respond with a communication regarding our key milestones, so that the building interest in the company can be understood in better perspective.'
The introductory letter to BSD Medical's fiscal 1999 report describes last year as one ``of intense investment in technology for BSD Medical Corporation. To build our intellectual property assets and to provide further certifications and infrastructure to support future growth, the company poured nearly half of its total investment in human resources into R&D and Engineering.'
In the first fiscal quarter of 1999 (the fiscal year begins in September), BSD announced the successful clinical testing of the new patented BSD-2000/3D system integrated with Magnetic Resonance Imaging (MRI) to create simultaneous heating and non-invasive treatment monitoring of deep regional hyperthermia. This culminated a five-year research effort funded in part by Phase I and II research grants from the National Cancer Institute, with collaborative efforts by Siemens Medical Systems and supported by similar efforts by the National Institute of Health and Duke University. The BSD-2000/3D System was designed to be effective in treating large, deep tumors, including breast, sarcoma, colorectal, cervical, bladder and prostate. The system capitalizes on BSD's patented three-dimensional adaptive electronic annular phased array (APA) focusing which optimizes treatment of deep tissue tumors.
In the second fiscal quarter BSD announced that it had received both ISO 9001 and 46001 certifications, qualifying the company as a manufacturer under the rigorous requirements of the International Organization of Standards. These new certifications positioned the company for dramatically improved access to foreign markets. During the quarter the company also announced issuance of the pioneering European patent for the BSD-2000/3D System. This patent was in addition to four U.S. patents already issued for the new equipment.
In the third quarter the company announced clinical acceptance of the BSD-2000/3D/MR by the LMU Munich University Medical School, which opened the way for the first purchases of the new product. Shortly thereafter the North American Hyperthermia Society reported that the BSD-2000/3D System provides optimized performance for the clinical treatment of deep regional tumors.
During its fourth quarter the company announced a BSD-2000/3D shipment for installation in Rotterdam, Netherlands. Following that installation, the Dutch Ministry of Health approved reimbursement for deep regional hyperthermia for treatment of advanced cervical cancer, and the European Society of Hyperthermic Oncology, convened in Rotterdam, reported many findings from all over the world that hyperthermia makes radiation and chemotherapy more effective in the treatment of cancer. BSD hired Hyrum A. Mead as its new President in August of the quarter. Mr. Mead brings a strong background in increasing corporate revenues and profits for growing companies. Mr. Mead's primary objectives are to strengthen the business leadership and build sales and marketing in the company.
During the first quarter of fiscal 2000, the Company announced an increased focus on U.S. markets, with the hiring of Harley Griffith, a seasoned Director of U.S. Sales, after an extensive national search. Mr. Griffith has an 18 year track record of success leading sales in such companies as Ciba-Geigy, where he was Director of Oncology Sales. In November 2000, BSD announced acquisition of the exclusive license to a microwave antenna from the University of California San Francisco (UCSF) with a ``tumor specific' heating length, highly desirable for supplemental use in conjunction with a popular cancer treatment known as ``brachytherapy.' The first quarter closed with the announcement of several orders for the BSD-2000/3D, including a large order from Berlin, Germany.
In the second fiscal quarter of 2000 (to end February 29th), BSD concluded an exhaustive qualification effort with the announcement of the long-awaited CE Mark for its proprietary BSD-2000/3D technology. From a marketing perspective, the CE Mark provides in Europe the advantage of an FDA approval in the United States. With the ISO 9001 and ECN 46001 certifications already in place, the CE Mark was the only credential remaining to bring the Company into compliance with all applicable harmonized EU standards. After years of research, development and clinical studies, BSD is finally able to offer to the European community the BSD-2000/3D and to begin to complete the backlog of European orders already received.
BSD Medical Corporation (BSDM) is the leading developer and manufacturer of hyperthermia systems for cancer therapy, and pioneered the non-surgical treatment of benign diseases of the prostate (BPH) using microwave energy for thermal therapy. For further information on the Company and its products, to find press releases detailing many other activities of the Company or to find hyperthermic oncology information sources and treatment centers, visit the BSD Medical Corporation web site (www.bsdmc.com).
Statements contained in this press release that are not historical facts are forward looking statements, as that item is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties (detailed in the Company's findings with the Securities and Exchange Commission) that could cause actual results to differ materially from estimated results.
SOURCE: BSD Medical Corporation
--------------------------------------------------------------------------------
More Quotes and News: BSD Medical Corp (OTC BB:BSDM.OB - news)
Related News Categories: biotech, medical/pharmaceutical
-------------------------------------------------------------------------------- |
